-
Tamoxifen and CYP2D6 inhibitors, FDA Actions, and FDA Warnings.
-
-
In this paper, Krahn et al from a Canadian consortium report on the results of systematic evaluations in patients with unexplained cardiac arrest due to ventricular tachycardia or ventricular fibrillation.
-
The debate continues as to whether coronary artery bypass graft (CABG) surgery with left-internal mammary artery (LIMA) or stenting is the best treatment for proximal left-anterior descending coronary artery (LAD) lesions.
-
This report from the Framingham heart study looks at the prognostic significance of PR interval prolongation in ambulatory, relatively healthy individuals.
-
Functional mitral regurgitation (FMR), occurring in heart failure, portends an adverse prognosis.
-
Pulmonary arterial hypertension (PAH) is a dreaded multifactorial disease that is usually fatal. PAH can be a result of a number of conditions, including chronic thromboembolic hypertension, HIV, and congenital cardiac lessons, such as a large ASD with pulmonary shunting resulting in decreased nitric oxide (NO) expression.
-
-
Hidradenitis suppurativa (HSP) is regarded both in the dermatology and primary care communities as a "heart sink" diagnosis: Patients are generally chronically burdened, we have little successful treatment, the pathophysiology is poorly understood, and the consequences often have an important negative impact on quality of life.
-
A new antiplatelet drug has been approved by the FDA for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.